We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rare Condition in Infant Diagnosed by Sequencing Exome

By LabMedica International staff writers
Posted on 29 Oct 2009
Focusing only on the small fraction of DNA that encodes proteins, the exome, investigators were able to diagnose a rare condition in an infant from Turkey.

Using high-throughput DNA sequencing, scientists identified a gene mutation that was responsible for the patient's disease but had not been suspected based on clinical observations.

Only about one percent of the human genome serves as blueprints for protein production. Mutations in these protein-coding regions can alter a protein's function or prevent it from being made at all--often with significant effects on health. For this reason, 85 % of mutations known to have major clinical effects occur in this small portion of the genome.

Starting with DNA from a blood sample from the patient--an infant in Turkey who was persistently dehydrated and failing to gain weight--the scientists found a gene mutation known to affect electrolyte transport in the intestines and cause a condition called congenital chloride diarrhea. Doctors in Turkey confirmed the diagnosis clinically and were able to provide a treatment tailored to the disease.

The team of Howard Hughes Medical Institute (HHMI; Chevy Chase, MD, USA) scientists led by Prof. Richard Lifton, M.D., Ph.D., chairman department of genetics at Yale School of medicine (New Haven, CT, USA) used a method they had developed for sequencing the exome to discover the gene mutation responsible for the infant's disease

"There have been questions about whether one would be able to accurately, comprehensively and quickly identify mutations in the genome using these approaches, and moreover whether one would then be able to make clinical sense of the resulting data. In this first case, we have demonstrated the utility of this technology, underscoring the potential for its broad use in the clinic," Prof. Lifton said. "As the cost of DNA sequencing continues to plummet, it seems clear that this technology will be useful for clinical diagnosis in a number of settings."

The method and diagnosis were reported in an advanced online publication of the U.S. Proceedings of the National Academy of Sciences (PNAS) on October 19, 2009.

Related Links:

Howard Hughes Medical Institute
Yale School of medicine



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer

Latest Molecular Diagnostics News

Genetic-Based Tool Predicts Survival Outcomes of Pancreatic Cancer Patients
29 Oct 2009  |   Molecular Diagnostics

Urine Test Diagnoses Early-Stage Prostate Cancer
29 Oct 2009  |   Molecular Diagnostics

New Genetic Tool Analyzes Umbilical Cord Blood to Predict Future Disease
29 Oct 2009  |   Molecular Diagnostics